NuvaRing improves cycle control in German women

NuvaRing improves cycle control in German women

S. Baumgaertner (1), E. Merkle (2)

Organon GmbH, Oberschleiheim, Germany (1); Private Practice, Bad

Reichenhall, Germany (2)

Introduction: Combined oral contraceptives (COCs) are often used for

many years, and many women may welcome a form of contraception that does not

require daily administration. NuvaRing is a once-a-month contraceptive vaginal

ring that releases 15 µg ethinylestradiol (EE) per day and has superior cycle

control compared with a COC containing 30 µg EE (data presented at this

meeting). This study was conducted to collect information on cycle control,

acceptability and tolerability in a large number of NuvaRing users in Germany.

Design and methods: This open, prospective, multi-centre study was

conducted by gynaecologists in general practices in Germany. Women expressing a

wish for contraception entered the study and used NuvaRing for 6 consecutive

cycles, each comprising 3 weeks of ring use followed by a 1-week ring-free

period. Information on cycle control, bleeding patterns and dysmenorrhoea was

recorded at baseline and after cycles 3 and 6.

Results: A total of 5823 subjects underwent all three examinations.

The mean age of the subjects was 29.4 years (SD 7.3). At baseline, 16.6% of

subjects had an irregular bleeding pattern, but by the final examination, this

decreased to 2.8%. Overall, duration of bleeding decreased from baseline to the

final visit as shown in the table, which shows the percentages of women with

different bleeding times.

  2–3 days 4–5 days 4–6 days 6–8 days 10–12 days
Baseline (%) 16.9   58.5 17.6 2.1 1.0
Final (%) 28.4   52.7 6.3 0.3 0.2

At baseline, 25.1% of subjects experienced mild bleeding and this increased

to 43.4% at the final visit. The proportion of subjects who experienced moderate

or severe bleeding at baseline decreased from 60.7% and 13.1%, respectively, to

44.5% and 2.4%, respectively, at the final visit. Breakthrough bleeding,

reported by 16.8% of subjects at baseline, decreased to 4.9% at the final visit.

The proportion of subjects who experienced dysmenorrhoea also decreased, from

25.9% at baseline to 5.7% by the final visit. The majority of subjects (81.8%)

were either satisfied or very satisfied with NuvaRing, and most (72.1%) intended

to continue using it after the study ended. Adverse events were recorded in 9.9%

of subjects. There were 19 serious adverse events, 5 of which were treatment


Conclusions: These results show that in addition to being an effective,

convenient and acceptable form of contraception, NuvaRing improves all aspects

of cycle control, including severity of bleeding, breakthrough bleeding and


Scroll to Top